← Leaderboards
Amy Patrice Skubitz
University Of Minnesota Twin Cities
$4,565,523
Attributed
$5,182,030
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $959.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,182,030 · 4
By mechanism
R01$4,807,371 · 3
P30$374,659 · 1
Top collaborators
- Facundo Martin Fernandez2 shared
- Jaeyeon Kim2 shared
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- John H Kersey$3,030,381
- David Andrew Largaespada$17,551,730
- Robert A Kratzke$784,066
- Leslie L Robison$40,900,702
- Timothy Robert Church$2,458,226
Others in their field
Top investigators on “Sampling”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Jeffrey P Krischer · University Of South Florida$522,319,685
- David R. Weir · University Of Michigan At Ann Arbor$421,002,438
- David Heimbrook · Leidos Biomedical Research, Inc.$410,224,927
- Eric S Lander · Whitehead Institute For Biomedical Res$395,613,296
- Richard A Gibbs · Baylor College Of Medicine$356,778,395
Research focus
SamplingLiquid SubstanceTumorResourcesDiagnosisTissuesSurvival RateBenignEarly DiagnosisDetectionTissue SampleBloodAscitesResearch PersonnelInstitutional Review BoardsBiological MarkersCodeDesignMalignant NeoplasmsProteinsBreastMinnesotaScreening ProcedureUniversities
Grant awards (19)
A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection$504,268
R01 · FY2025 · CA · contact PI
Deep Ovarian Cancer Metabolomics$447,948
R01 · FY2025 · CA
A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection$482,485
R01 · FY2024 · CA · contact PI
Deep Ovarian Cancer Metabolomics$476,813
R01 · FY2024 · CA
A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection$494,053
R01 · FY2023 · CA · contact PI
A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection$527,313
R01 · FY2022 · CA · contact PI
A paradigm shift for ovarian cancer biomarkers: Utilizing routine Pap tests as liquid biopsies for the development of targeted mass spectrometry-based proteomic assays for early detection$477,872
R01 · FY2021 · CA · contact PI
Tissue Procurement Facility$91,853
P30 · FY2013 · CA · contact PI
Tissue Procurement Facility$65,228
P30 · FY2012 · CA · contact PI
Tissue Procurement Facility$2,678
P30 · FY2012 · CA · contact PI
Tissue Procurement Facility$1,775
P30 · FY2012 · CA · contact PI
Tissue Procurement Facility$70,471
P30 · FY2011 · CA · contact PI
Tissue Procurement Facility$73,410
P30 · FY2010 · CA · contact PI
Biomarkers with Biological Function in Ovarian Carcinoma$274,365
R01 · FY2009 · CA · contact PI
Tissue Procurement Facility$69,244
P30 · FY2009 · CA · contact PI
Biomarkers with Biological Function in Ovarian Carcinoma$283,150
R01 · FY2008 · CA · contact PI
Biomarkers with Biological Function in Ovarian Carcinoma$271,860
R01 · FY2007 · CA · contact PI
Biomarkers with Biological Function in Ovarian Carcinoma$282,699
R01 · FY2006 · CA · contact PI
Biomarkers with Biological Function in Ovarian Carcinoma$284,545
R01 · FY2005 · CA